摘要
姜黄色素和聚乙二醇负载姜黄素抑制肿瘤作用的实验研究
目的 ①研究姜黄素及其衍生物(统称为姜黄色素)对不同细胞系和对小鼠肿瘤生长的影响，探讨姜黄素及其衍生物抑制肿瘤的作用机理。②研究聚乙二醇负载姜黄素对小鼠肉瘤(S_(180))的影响，探讨其抗肿瘤的作用机理。
方法 ①用MTT法检测姜黄素及其衍生物对牛主动脉平滑肌、人脐静脉内皮细胞ECV-304和人胃癌细胞SGC-7901增殖的影响。②用琼脂糖刮除法检测姜黄素及其衍生物对牛血清促进人脐静脉内皮细胞ECV-304迁移的影响。③利用整体动物制作肿瘤模型，从整体上观察姜黄素及聚乙二醇负载的姜黄素对肿瘤生长的影响。
结果 ①姜黄素及其衍生物对牛主动脉平滑肌、人脐静脉内皮细胞ECV-304和人胃癌细胞SGC-7901增殖有不同的抑制作用；相同浓度下对内皮细胞的抑制率明显大于对肿瘤细胞、平滑肌细胞的抑制率。②姜黄素及其衍生物能显著抑制牛血清培养液中人脐静脉内皮细胞ECV-304的迁移。③姜黄素及聚乙二醇负载的姜黄素对肿
瘤生长均有明显的抑制作用，后者的抑瘤率高于前者。
结论①姜黄素及其衍生物具有抑制内皮细胞迁移
和特异性地抑制内皮细胞增殖，因而具有抑制血管生成
作用，可以认为姜黄素是一种血管生成抑制剂，并且是一
种特异性的血管生成抑制剂。②姜黄素及聚乙二醇负载的
姜黄素对肿瘤生长均有明显的抑制作用，后者的抑瘤率高
于前者，并且聚乙二醇的分子量越大，抑制作用越明显。
Objective (1)To investigate the effect of curcumin and its derivatives on various cell lines and growth of tumor in mice and discuss the mechanism of it. (2)To investigate the effect of poly(ethylene glycol)(PEG) conjugated curcumin on Sarcocarcinoma(S180) in mice and its probable mechanism.
Methods (1)MTT reduction assay was taken to observe the effect of curcumin and its derivatives on proliferation of bovine aortic smooth muscle cells(BASMCs), human umbilical vein endothelial cells(ECV-304) and human stomach adenocarcinoma cell line(SGC-7901) maintained in medium containing 10% fetal bovine serum(FBS).(2)The effect of curcumin and its derivatives on the migration of ECV-304 maitained in medium containing 10% FBS was investigated by agorose assay. (3)The mouse tumor model was used to investigate the effect of curcumin and PEG conjugated curcumin on tumor growth.
Results (1)The inhibitory effect on the proliferation of ECV-304, SGC-7901 and BASMCs by curcumin and its derivatives are different. (2)Curcumin and its derivatives can significantly inhibit the migration of ECV-304 induced by FBS. (3)Curcumin and its derivatives and PEG conjugated curcumin have remarkable inhibitory effect on the tumor growth.
Conclusion (1)Curcumin and its derivatives can significantly inhibit the proliferation and migration of ECV-304 induced by FBS, thus can inhibit angiogenesis. (2)Curcumin and its derivatives and PEG conjugated curcumin have remarkable inhibitory effect on the tumor growth. The inhibitory effect of PEG conjugated curcumin on tumor excels that of Curcumin and its derivatives.The inhibitory effect is paralleled with molecular weight of PEG.
引文
1 Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases.Nature,2000,407(6801):249～257.
2 Ryan CJ, Wilding G. Angiogenesis inhibitors. New agents in cancer therapy. Drugs Aging, 2000,17(4):249～255.
3 韩婷，宓鹤鸣．姜黄的化学成分及药理活性研究进展．解放军药学学报，2001，17(2)：95～97．
4 Greenwald RB. PEG drugs:an overview. Joumal of Controlled Release,2001,74:159～171.
5 鄂征．组织培养和分子细胞学技术．北京，北京出版社，2001．
6 黄燕芬，洪行球．分光光度法测定总姜黄素的含量及方法学考察．浙江中医学院学报，1999，23(6)：24～25．
7 Trochon V, Mabilat C, Bertrand P, et al. Evidence of involvement of CD44 in endothelial cell proliferation, migration and angiogeness in vitro.Int J Cancer, 1996,66(5):664～668.
8 Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases.Nature, 2000,407(6801):249～257.
9 Folkman J. Angiogenesis in cancer,vascular, theumatoid and other disease. Nature Med, 1995,1(1):27～31.
10 Folkman J. Clinical applications of research on angiogenesis. N Engl J Med, 1995,333(26): 1757～1763.
11 Cao Y. Therapeutic potentials of angiostatin in the treatment of cancer. Haematologica, 1999,84(7):643～650.
12 Hanada D, Folkman J. Patterns and emerging mechanisms of the
angiogenic switch during tumorigenesis. Cell, 1996;86(3):353～364.
13 许建华，赵蓉，柯丹如，等．姜黄素对人肝癌Bel7402细胞杀伤动力学及周期时相的影响．福建医科大学学报，1998，32(3)：236～239．
14 陈文娟，陈燕，吴裕丹，等．姜黄素调节HL-60细胞周期蛋白表达的研究．临床血液学杂志，2001，14(5)：215～217．
15 孟秀香，巩静，孙宏丹，等．姜黄素在体外对白血病细胞及其时相性影响的观察．白血病，2000，9(3)：147～150．
16 丁志山，高承贤，陈铌铍，等．姜黄素具有抑制血管生成与诱导肿瘤细胞凋亡双重作用．中国药理学通报，2003，19(2)：171～173．
17 Molema G, Deleij LF, Meijer DK, et al. Tumor vascular endothelium: barrier target in tumor dirrected drug delivery and immunotherapy. Pharm Res, 1997,14(1):2～10.
18 李金亮，冯霞，刘斌，等．聚乙二醇支载水溶性紫杉醇衍生物的合成．天津大学学报，2001，34(6)：808～811．
19 Greenwald RB, Conover CD, Annapurna Pendri, et al. Drug delivery of anticancer agents: water soluble 4-poly(ethylene glycol) derivativesof the lignan, podophyllotoxin. Journal of Controlled Release,1999,61:281～294.
20 Molineux G. Pegylation: engineering improved pharmaceuticals for enhanced therapy. Cancer Treat Rev 2002,28 Suppl A:13～6.
21 Bhadra D, Bhadra S, Jain P, et al. Pegnology: a review of PEG-ylated systems. Pharmazie, 2002,57(1):5～29.
22 姜忠义，许松伟．生物分析化学修饰用聚乙二醇衍生物的合成及应用．高分子通报，2002，(2)：34．
23 Shao J. Development of novel drug delivery systems. Trends Pharmacol Sci, 2002,23(1):47.
24 Creson CR, Jones DJ, Orr S, et al. Metabolism of the cancer chemopreventive agent curcumin in human and rat intestine. Cancer Epidemiol Biomarkers Prev. 2002,11(1):105.
25 段聂晶．水溶性姜黄色素的提取及其理化性质研究，湖北化工，1997，(1)：26．
26 Shoba G. Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers. Planta Med, 1998, 64(4):353.